EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 15-Jul-2025 17:11 ET (15-Jul-2025 21:11 GMT/UTC)

Immunotherapy improves survival of patients with locally advanced head and neck cancer

WashU Medicine
Reports and Proceedings

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

Funder: Merck Sharp & Dohme LLC
Meeting: AACR Annual Meeting 2025

Oral investigational agent zoldonrasib elicits objective responses in patients with KRAS G12D-mutated lung cancer

American Association for Cancer Research
Reports and Proceedings

The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell #LungCancer in a phase I clinical trial, according to results presented by Kathryn C. Arbour, MD, at the AACR Annual Meeting 2025.

Meeting: AACR Annual Meeting 2025

AACR announces 2025 Scientific Achievement Award recipients

American Association for Cancer Research
Grant and Award Announcement

CHICAGO – The American Association for Cancer Research (AACR) will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.

Meeting: AACR Annual Meeting 2025

AACR announces 2025 Distinguished Public Service Award recipients

American Association for Cancer Research
Grant and Award Announcement

The American Association for Cancer Research (AACR) will honor leaders from government and the advocacy community with 2025 AACR Distinguished Public Service Awards at the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.

Meeting: AACR Annual Meeting 2025

Richard Pazdur, MD, honored with the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

American Association for Cancer Research
Grant and Award Announcement

The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented to Richard Pazdur, MD, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois. Pazdur will accept the award and give remarks during the meeting’s Opening Ceremony on Sunday, April 27, which begins at 7:45 a.m. CT.

Meeting: AACR Annual Meeting 2025

AACR launches its largest-ever grant program to support early-stage and mid-career cancer researchers

American Association for Cancer Research
Grant and Award Announcement

The American Association for Cancer Research (AACR) today announced the launch of the AACR Trailblazer Cancer Research Grant Program during the Opening Ceremony of the AACR Annual Meeting 2025. This bold new grant program will award 15 grants of $1 million each to early-stage and mid-career investigators to support meritorious and promising cancer research.

Meeting: AACR Annual Meeting 2025

Triggers 'cellular storm' for smart tumor elimination

Science China Press
Peer-Reviewed Publication

Novel cancer therapy combining multi-hydroxylated fullerene (MF) nanoparticles and mTOR inhibitors triggers organelle cascade collapse in tumors, disrupting cancer cells' self-repair capacity. By synchronizing the membrane-breaking effect of MF with dual autophagy regulation, this strategy induces lysosomal rupture, mitochondrial dysfunction, and endoplasmic reticulum stress while paralyzing cellular cleanup systems. Animal studies demonstrate potent tumor suppression and high safety, leveraging cancer cells' fragile organelle networks against them. The breakthrough establishes organelle communication disruption as a new anticancer paradigm, pioneering material science-enabled therapies independent of genetic targets.

Journal: Science Bulletin

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

University of Pennsylvania School of Medicine
Peer-Reviewed Publication

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000—until recently. Thanks to changes in Medicare Part D introduced by the Inflation Reduction Act (IRA) that took effect in 2025, annual out-of-pocket drug costs for all beneficiaries are now capped at $2,000. However, an overlooked voluntary program that’s part of the IRA could be the key to improving affordability for Medicare patients needing expensive oral cancer drugs, according to a new study from researchers from the Perelman School of Medicine at the University of Pennsylvania published today in JCO Oncology Practice.

Journal: JCO Oncology Practice

City of Hope scientists present leading-edge research at American Association for Cancer Research (AACR) Annual Meeting

City of Hope
Meeting Announcement

Researchers at City of Hope will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options at the AACR Annual Meeting, which started April 25 and ends April 30 in Chicago.

Meeting: AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancreatic cancer.

91
92
93
94
95